Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

NCT03379259 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Stopped Study Was Terminated Early

Conditions

Advanced Solid Tumors

Interventions

DRUG: BGB-A333
DRUG: BGB-A317

Sponsor

BeiGene